This article was originally published in The Gray Sheet
USSC is discontinuing development and plans to commercialize InnerDyne's EnAbl thermal endometrial ablation system for treatment of excessive uterine bleeding, InnerDyne reports Aug. 28. InnerDyne cites as a possible reason for the decision USSC's acquisition of a "competing technology" via its $425 mil. Valleylab purchase in February. The move follows FDA's March approval of USSC's product development protocol for the system ("The Gray Sheet" March 16, In Brief). The two firms agreed to a marketing deal for the product in early 1997
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.